These findings suggest that JAML may play a crucial role in the pathogenesis of renal IRI and subsequent tubular injury, potentially serving as a novel biomarker or therapeutic target in acute kidney injury (AKI) management (Huang et al., 2022; Gu et al., 2022). The gene discussed is JAML; the disease is acute kidney injury.